We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Celldex Presents Positive Results from Phase 2 Study of ADC Product Candidate CDX-011 in Breast Cancer
News

Celldex Presents Positive Results from Phase 2 Study of ADC Product Candidate CDX-011 in Breast Cancer

Celldex Presents Positive Results from Phase 2 Study of ADC Product Candidate CDX-011 in Breast Cancer
News

Celldex Presents Positive Results from Phase 2 Study of ADC Product Candidate CDX-011 in Breast Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Celldex Presents Positive Results from Phase 2 Study of ADC Product Candidate CDX-011 in Breast Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Celldex Therapeutics, Inc. has announced the results of a positive Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in patients with heavily pre-treated, locally advanced or metastatic breast cancers.

As presented the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, the primary efficacy endpoint for the study has been met with significant antitumor activity in patients whose tumors express the target GPNMB.

In addition, encouraging results were seen in patients with “triple-negative disease” where treatment options are relatively limited due to lack of hormone receptor or HER2-neu expression.

CDX-011 is the first candidate from the Company’s antibody-drug conjugate (ADC) platform, which utilizes fully human monoclonal antibodies to deliver the potent cellular toxin, MMAE, directly to tumor cells by targeting GPNMB.

GPNMB is a glycoprotein frequently expressed in a number of tumor types and associated with cancer progression and recurrence. CDX-011 uses the Seattle Genetics MMAE ADC technology, which has established a very promising antitumor effect in advanced clinical studies.
Advertisement